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1. Introduction/Abstract 1 
During the early stages of the COVID-19 pandemic, EASL and ESCMID published a position 2 
paper to provide guidance for physicians involved in the care of patients with chronic liver 3 
disease. In the meantime, many countries and healthcare systems have been, or are still 4 
overwhelmed by the pandemic, significantly impacting on the care of this group of patients, 5 
whilst others have started to return towards their usual routine. In addition, many studies have 6 
been published focusing on how COVID-19 may affect the liver and how pre-existing liver 7 
diseases might influence the clinical course of COVID-19. While many aspects remain poorly 8 
understood, it has become increasingly evident that pre-existing liver diseases and liver injury 9 
during the course of the disease have to be kept in mind when caring for patients with COVID-10 
19. Thus, this review should serve as an update on the previous position paper summarizing the 11 
evidence for liver disease involvement during COVID-19 and also provide some 12 
recommendations on how to return to routine care wherever possible. 13 
 14 
2. Pre-existing liver disease as risk factor for CO VID-19 15 
Patients with chronic liver diseases per se do not appear to be over-represented in cohorts of 16 
patients with COVID-19 where they represent less than 1% of reported cases [1, 2]. These 17 
observations suggest that patients with chronic liver disease are not at increased risk of 18 
contracting SARS-CoV-2. However, risk of infection and/or risk for severe course of COVID-19 19 
may be different depending on the nature of the chronic liver disease and the presence or 20 
absence of advanced fibrosis or cirrhosis. We will therefore summarize current evidence for 21 
different liver diseases regarding the risk for SARS-CoV-2 infection and for a severe course of 22 
COVID-19. 23 
 24 
Metabolic-dysfunction associated fatty liver disease (MAFLD) 25 
Obesity represents a significant risk factor for a severe course of COVID-19 [3, 4] with severe 26 
pneumonia being particularly increased in obese men [3]. While the precise mechanisms driving 27 
this association remain unclear, it has been postulated that adipose tissue may serve both as a 28 
viral reservoir and also an immunological hub for the inflammatory response [5]. Similarly, other 29 
metabolic syndrome elements such as hypertension and diabetes are commonly observed in 30 
patients with severe COVID-19 [6]. As metabolic dysfunction-associated fatty liver disease 31 
(MAFLD, previously known as non-alcoholic fatty liver disease, NAFLD) [7] and non-alcoholic 32 
steatohepatitis (NASH) are closely associated with these metabolic comorbidities, it is of 33 
relevance to identify whether presence of MAFLD specifically predisposes to a more severe 34 
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course of COVID-19. A retrospective cohort of 202 patients with COVID-19 demonstrated an 1 
association between MAFLD and disease progression defined as deteriorating dyspnoea, 2 
hypoxia or radiological findings whilst in hospital [8]. This additional risk has been observed 3 
even in younger patients with MAFLD [9] and in the absence of type 2 diabetes [10] and 4 
interestingly, patients with MAFLD also appear to have a longer duration of viral shedding [8]. 5 
Within patients with MAFLD, non-invasive fibrosis scores appear to correlate with higher 6 
likelihood of developing severe COVID-19 illness, irrespective of metabolic comorbidities [11], 7 
however, genetic polymorphisms implicated in the development and progression of NASH do 8 
not appear to be associated with severe disease [12, 13]. In addition, transcriptional activity of 9 
genes relevant for SARS-CoV-2-infection has not been found to be increased in liver-tissues of 10 
MAFLD patients [14]. Larger analyses are needed to determine whether MAFLD is an 11 
independent risk factors for a poor prognosis in COVID-19 or whether the reported effects are 12 
due to the presence of confounding factors. 13 
 14 
Chronic viral hepatitis 15 
In contrast to metabolic liver disease, little or no evidence has emerged to suggest that the 16 
presence of chronic viral hepatitis affects the COVID-19 disease course. Data from both an 17 
international registry and from a multicenter cohort study in Italy on COVID-19 outcomes in 18 
patients with chronic liver disease include patients with viral hepatitis (23%-37%). However, 19 
despite both studies demonstrating associations between severity of liver disease and poor 20 
outcome, it remains unknown whether the presence of chronic viral hepatitis influences 21 
prognosis [15, 16].   22 
 23 
Autoimmune hepatitis 24 
In the previous position paper, we advised against the withdrawal of established 25 
immunosuppressive therapy in patients with autoimmune liver disease [17] and a panel of 26 
experts on autoimmune liver disease have subsequently given similar recommendations [18]. 27 
While there is still little evidence to demonstrate that immunosuppressive therapy per se 28 
predisposes to SARS-CoV-2 infection, a handful of observational studies have suggested an 29 
association between corticosteroid use and a more severe COVID-19 disease course [19-23]. 30 
The potential implications of these observations are discussed below in more detail. Further 31 
data are needed to determine whether the specific risk of COVID-19 is increased in patients 32 
with autoimmune hepatitis and the influence of steroids and/or other immunosuppressive 33 





Patients with liver cirrhosis are at increased risk for infections and associated complications due 3 
to cirrhosis-associated immune dysfunctions, which is particularly important for patients with 4 
decompensated cirrhosis. A recent case-series from China reported that from 21 consecutive 5 
patients with pre-existing cirrhosis, 5 did not survive SARS-CoV-2-infection [24] and specifically 6 
patients with Child-Pugh class C cirrhosis were more likely to suffer a fatal course of COVID-19 7 
[24, 25]. Another case series from Italy documented 50 patients with cirrhosis and COVID-19; 8 
26% of these patients presented with MELD ≥15, increasing from 13% at the last documented 9 
visit prior to SARS-Cov-2 infection. The 30 day mortality was 34%, with end-stage-liver disease 10 
considered as the cause of death in only 5 patients (29%) whilst respiratory failure due to 11 
COVID-19 accounted for death in 12 patients (71%) [15]. These data are in line with 12 
observations from a European registry that reported the outcome of 103 patients with cirrhosis - 13 
nearly 40% died with patients with Child-Pugh class C cirrhosis at the highest risk for a fatal 14 
course of COVID-19 (63%, n= 27) [16]. Similarly, multicentre hospital coding data in the USA 15 
demonstrated a significantly higher risk of mortality from COVID-19 in patients with chronic liver 16 
disease compared to those without, with the highest risk found in those with cirrhosis [26]. 17 
However, these data did not have a contemporaneous comparison group of patients with 18 
cirrhosis presenting with acute decompensation without COVID-19. Recently, a prospective 19 
multicentre study compared outcomes between patients with cirrhosis and COVID-19 (n=37), 20 
cirrhosis alone (n=127) and COVID-19 alone (n=108). Although rates of mortality or transfer to 21 
hospice in patients with cirrhosis and COVID-19 was greater than COVID-19 alone (30% vs 22 
13%, p=0.03) there was no significant difference from cirrhosis alone (30% v. 20%; p=0.11). 23 
The presence of acute-on-chronic liver failure (ACLF) was also similar in the two cirrhosis 24 
groups (29.7% vs 22.8%) as was mortality in ACLF patients (55% v. 36%; p=0.25) although the 25 
number of cases was small [27]. Taken together, currently it is difficult to conclude that the 26 
occurrence of COVID-19 in cirrhosis patients increases the risk of developing ACLF or mortality 27 
compared with those patients that decompensate with cirrhosis due to other reasons. However, 28 
the mortality of cirrhosis patients with COVID-19 is markedly greater than those that do not have 29 
cirrhosis. 30 
 31 
Liver Transplantation (LT) recipients 32 
The clinical course of COVID-19 in immunosuppressed transplant recipients may differ from 33 
those in non-immunosuppressed patients [28]. Indeed, while hepatocellular injury, as 34 
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characterized by elevated serum aminotransferases, appears to be relatively less prevalent, 1 
acute kidney injury is more common in transplant recipients with COVID-19, possibly due to the 2 
use of calcineurin inhibitors [28]. These findings will need confirmation in larger case series; 3 
however, in line with the general risk factors for severe COVID-19, elderly patients with 4 
comorbidities are among those with the highest risk within the cohort of transplant recipients 5 
[28, 29]. Early reports from Italy described low mortality rates in transplant recipients < 5% [20, 6 
30], however subsequent analyses have reported mortality rates in liver and other solid organ 7 
transplant recipients at around 25% [28, 31-34]. The results of a prospective European study 8 
from 19 transplant centres were recently reported [35] including 57 LT recipients with confirmed 9 
SARS-CoV-2 infection. Overall and in-hospital case-fatality rates were 12% and 17% 10 
respectively, which are similar to the expected mortality for patients with severe COVID-19 11 
infection. Five of the 7 patients who died had an underlying history of cancer. Taken together 12 
the currently available data do not support the notion that transplantation or specific 13 
immunosuppressive regimens significantly affect the risk for a severe course of COVID-19 but 14 
those with underlying cancer may require special attention [28, 31, 35]. 15 
 16 
3. Liver injury secondary to COVID-19  17 
Deranged liver biochemistry of varying degrees is common in patients with COVID-19, being 18 
found in 19-76% of cases [36-41]. Most of these studies report a predominantly hepatocellular 19 
pattern of liver injury with elevated serum aminotransferases (rarely > 5 x upper limit of normal) 20 
although cholestatic or mixed patterns of liver injury have also been reported. Importantly, this 21 
appears to occur to a similar degree in patients with and without pre-existing liver disease [26] 22 
and has also been documented in pregnant women in association with increased levels of pro-23 
inflammatory cytokines [42]. To what extent this liver injury is derived from the direct effect of 24 
SARS-CoV-2, as opposed to a secondary phenomenon caused by the broader disease course 25 
of COVID-19 remains to be elucidated.  SARS-CoV-2 infection of hepatocytes with subsequent 26 
mitochondrial disturbance and apoptosis has been suggested [41], but requires confirmatory 27 
testing particularly since single cell RNA sequencing has shown relatively sparse hepatocyte 28 
expression of the receptors necessary for viral uptake [43]. Similarly, direct infection of 29 
cholangiocytes via angiotensin-converting enzyme 2 (ACE2) has been posited as a potential 30 
mechanism for intrinsic liver injury [44] but requires further investigation. Given the profound 31 
multi-systemic involvement of COVID-19, particularly in the severe and critical forms of disease, 32 
liver injury is likely to be multifactorial with contributions from systemic inflammation, intrahepatic 33 
immune activation, microvascular thrombosis, hepatic congestion, perturbations of the gut-liver-34 
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axis as well as drug toxicity [45-48]. The prognostic significance of deranged biochemistry in 1 
COVID-19 remains unresolved [49]; some groups have demonstrated a strong correlation with 2 
duration of hospitalisation, organ failure and intensive care unit admission [37, 41, 50] whilst 3 
others have failed to observe any significant associations with outcome [39, 40].  4 
 5 
 6 
4. Recommendations for the management of patients w ith chronic liver disease 7 
 8 
General recommendations 9 
In the aftermath of COVID-19 at its peak, there was an urgent need to anticipate and plan for 10 
the wave of liver disease yet to come. This will be characterised by emergent hepatic 11 
decompensation, increased dropouts from transplant waiting lists and a vast back-log of 12 
deferred hospital visits and testing [51]. Clinicians and their institutions should therefore be 13 
proactive in structuring their services to tackle these challenges and strive to resume standard-14 
of-care for patients with liver disease wherever possible. Equally, it is important to embrace 15 
innovative technologies and methods of practice developed during the pandemic which may 16 
continue to be of benefit to patients (e.g. telemedicine use, remote monitoring) [52].  Combining 17 
standard of care with novel ideas will help to mitigate against longer term consequences of the 18 
pandemic including missed diagnosis, incomplete HCC screening, and progressive liver 19 
disease. Furthermore, in light of accumulating evidence that baseline liver disease severity is 20 
associated with poor outcomes from COVID-19 [15, 16], treatment of underlying liver disease 21 
may represent one of the most important strategies to protect patients from the adverse effects 22 
of any future SARS-CoV-2 infection. This in turn will further reduce the burden on healthcare 23 
systems and allow more rapid return towards gold standard hepatology practice (Fig 1). The 24 
epidemiology of COVID-19 has proven unpredictable, but the burden of disease is likely to 25 
expand and shrink episodically within populations for some time to come. The approach to 26 
patient care must therefore be personalised and flexible, balancing national dynamics of SARS-27 
CoV-2 infection, the local resource availability, and the severity of each individual patient's 28 
underlying liver disease. Lastly, with time, it will be important to resume clinical trial enrolment 29 
wherever possible to allow the field to advance despite unprecedented global events.   30 
   31 
 32 





• Patients should be made aware of potential adverse metabolic and hepatic consequences of 2 
social isolation including more sedentary lifestyles and increased consumption of processed 3 
foods.  4 
• Preventing liver disease progression through intensive lifestyle intervention, including 5 
nutritional guidance, weight loss advice, and diabetes management may help prevent the 6 
development of a severe disease course with future SARS-CoV-2 infection.  7 
• Treatment of arterial hypertension should continue in accordance with existing guidelines. 8 
There is currently no evidence showing that angiotensin converting enzyme inhibitors 9 
(ACEIs) or angiotensin receptor blockers (ARBs) increase the risk of SARS-CoV-2 infection 10 
or the risk of developing severe complications or death from COVID-19 [53].  11 
• Early admission should be considered for all patients with MAFLD who become infected with 12 
SARS-CoV-2. 13 
 14 
Viral hepatitis 15 
• Continue treatment of chronic hepatitis C virus (HCV) and chronic hepatitis B virus (HBV) if 16 
already receiving treatment.  17 
• Use telemedicine/local laboratory testing for follow-up visits in patients receiving antiviral 18 
therapy, send follow-up-prescriptions by mail and supply extended prescription supplies 19 
including full course of direct acting antiviral (DAA) medications to complete HCV treatment 20 
if this has been initiated. However, patients with poor compliance with medications should 21 
be considered for directly observed treatment protocols. 22 
• In patients without COVID-19, treatment for HCV and HBV should be initiated according to 23 
general guidelines [54, 55]. 24 
• Given the unknown impact of interferon alpha on systemic inflammation associated with 25 
COVID-19, alternative agents should be considered when initiating treatment for patients 26 
with HBV during the COVID-19 pandemic.  27 
• In patients with COVID-19, initiation of treatment for HBV and HCV is usually not warranted 28 
and should be deferred until recovery from COVID-19. 29 
• In patients with COVID-19 in whom there is evidence of high disease activity (flare) or 30 
clinical suspicion for severe acute HBV hepatitis, a decision to initiate antiviral therapy 31 
should be made on a case-by-case basis in consultation with a specialist.  32 
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• In patients with chronic, occult or resolved HBV and COVID-19 receiving corticosteroids, 1 
tocilizumab or other immunosuppressive agents, consider the use of antiviral therapy to 2 
prevent viral flare or reactivation. 3 
• Continue to work towards the WHO goal of eliminating viral hepatitis by 2030 by trying to 4 
adapt the cascade-of-care to the new coronavirus situation and make modifications for safe 5 
delivery of services according to the local requirements. 6 
 7 
Alcohol associated liver disease 8 
• Chronic alcohol consumption may increase susceptibility of acute respiratory distress 9 
syndrome (ARDS) secondary to SARS-CoV-2 infection [56]. 10 
• Social isolation can lead to new or increased alcohol consumption [57] and an increase in 11 
alcohol related admissions including new hepatic decompensation should be anticipated 12 
during and after periods of physical distancing.  13 
• Clinicians and institutions should therefore implement pre-emptive strategies such as patient 14 
outreach and telephone alcohol liaison and cessation services.  15 
• Whilst introducing corticosteroids has shown benefit in the treatment of hospitalised patients 16 
with COVID-19 requiring respiratory support [58], concerns remain that patients who are 17 
already taking higher doses of corticosteroids may be more susceptible to severe COVID-19 18 
[19, 59]. These concerns must be considered when initiating corticosteroids as a treatment 19 
for patients with severe alcoholic hepatitis.  20 
• Clinicians should be aware of circulating false online misinformation regarding the protective 21 
effects of alcohol against SARS-CoV-2 leading to previous instances of deliberate excess 22 
consumption [60].  23 
 24 
Autoimmune liver disease 25 
• In patients with autoimmune liver disease, we currently advise against reducing 26 
immunosuppressive therapy to prevent SARS-CoV-2 infection. Reductions should only be 27 
considered under special circumstances (e.g. medication-induced lymphopenia, or bacterial/ 28 
fungal superinfection in cases of severe COVID-19) after consultation with a specialist. 29 
• Whilst introducing corticosteroids has shown benefit in the treatment of hospitalised patients 30 
with COVID-19 requiring respiratory support [58], concerns remain that patients who are 31 
already taking higher doses of corticosteroids may be more susceptible to SARS-CoV-2 32 
infection and severe COVID-19 [19, 59]. To minimise systemic glucocorticoid exposure we 33 
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therefore recommend considering budesonide as a first-line agent to induce remission in 1 
patients without cirrhosis who have a flare of autoimmune hepatitis [61]. 2 
• In patients treated with corticosteroids who develop COVID-19, corticosteroid dosing should 3 
be sufficient to prevent adrenal insufficiency. Addition of, or conversion to dexamethasone 4 
should only be considered in patients with COVID-19 who require hospitalisation and 5 
respiratory support [58].   6 
• There remains a paucity of data to make specific recommendations for patients with primary 7 
biliary cholangitis, primary sclerosing cholangitis and IgG4-related disease.  8 
• All patients should receive vaccination for Streptococcus pneumoniae and influenza 9 
 10 
Cirrhosis 11 
• Patients with cirrhosis are particularly vulnerable to both the consequences of SARS-CoV-2 12 
infection and to the adverse effects of delayed or altered standard of care during the 13 
COVID-19 pandemic.  14 
• Every effort should be made to resume the best standard of care for patients with cirrhosis 15 
according to guidelines [62] wherever possible. 16 
• Patients with cirrhosis who are infected with SARS-CoV-2 are at high risk of new or 17 
worsening hepatic decompensation, severe COVID-19 and death [15, 16]. 18 
• All patients with new or worsening hepatic decompensation or acute-on-chronic liver failure 19 
(ACLF) should be prioritised for SARS-CoV-2 testing even in the absence of respiratory 20 
symptoms [16].  21 
• In those with cirrhosis who are admitted for reasons other than COVID-19, particular effort 22 
should be made to manage these patients in a designated non-COVID-19 ward, preferably 23 
in a side-room, in order to reduce the risk of nosocomial SARS-CoV-2 infection.  24 
• Guidelines on prophylaxis of spontaneous bacterial peritonitis, gastrointestinal 25 
haemorrhage, and hepatic encephalopathy should be closely followed to prevent 26 
decompensation and avoid admission [62]. 27 
• Early admission should be considered for all patients with cirrhosis who become infected 28 
with SARS-CoV-2. 29 
• Because of the potential of circulatory dysfunction, in particular in the pulmonary circulation 30 
associated with COVID-19 [63], the use of vasoconstrictor therapy, which is known to 31 
increase pulmonary pressure and decrease cardiac output, should be considered with great 32 
caution among critically ill patients with cirrhosis and COVID-19. 33 
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• Rapid clinical deterioration in patients with advanced liver disease and COVID-19 should 1 
prompt consideration of a symptoms-based approach using palliative care guidelines [64].  2 
• All patients should receive vaccination for Streptococcus pneumoniae and influenza. 3 
 4 
Liver transplant (LT) candidates 5 
• Patients on the LT waiting list with decompensated cirrhosis are at high risk of severe 6 
COVID-19 and death following SARS-CoV-2 infection.  7 
• We therefore recommend LT centers aim to restore transplantation services following the 8 
peak of the COVID-19 epidemic wherever possible.  9 
• In centers with ongoing resource limitations, LT should be prioritized for patients with poor 10 
short-term prognosis including those with acute/acute-on-chronic liver failure (ALF/ACLF), 11 
high model for end-stage liver disease (MELD) score (including exceptional MELDs) and 12 
HCC at the upper limits of the Milan criteria. 13 
• The risk of SARS-CoV-2 transmission via liver transplantation remains unknown [65] and 14 
therefore we currently recommend to test all donors for SARS-CoV-2 infection by RT-PCR 15 
and recommend against using livers from SARS-CoV-2 infected donors [66].  16 
• We encourage LT centres to develop and improve local and global risk stratification 17 
pathways for LT donors and recipients incorporating a combination of clinical history, chest 18 
radiology, and SARS-CoV-2 testing [67] and ethical considerations regarding transplantation 19 
activities and allocation [68]. 20 
• Measures should be taken to reduce the risk of SARS-CoV-2 infection in the peri-21 
transplantation period. In areas of high disease burden, a COVID-19 free pathway through 22 
transplantation should be implemented including strict social isolation for waiting list 23 
patients, telephone screening for symptoms and exposures before admission, and 24 
perioperative management in a designated clean ICU and post-LT ward [69].  25 
• Consent for diagnostic and therapeutic procedures related to transplantation should include 26 
the potential risk of nosocomial COVID-19. 27 
• LT candidates should be made aware that infection with SARS-CoV-2 in patients 28 
undergoing major surgery is associated with an increased risk of severe COVID-19 and 29 
death [70]. 30 
• Living-donor transplantations should be considered on a case-by-case basis and include 31 
careful risk stratification of donor and recipient incorporating a combination of clinical history, 32 
chest radiology, and SARS-CoV-2 testing. 33 
  34 
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LT recipients 1 
• We advise against reduction of immunosuppressive therapy to prevent SARS-CoV-2 2 
infection. Reduction should only be considered under special circumstances (e.g. 3 
medication-induced lymphopenia, or bacterial/fungal superinfection in case of severe 4 
COVID-19) after consultation with a specialist. 5 
• Clinicians must be aware of the high reported rates of fear and anxiety regarding COVID-19  6 
in LT recipients and the barrier this may pose to compliance with immunosuppressive 7 
medication and attendance at scheduled medical visits [71]. 8 
• Drug levels of calcineurin inhibitors and mechanistic Target of Rapamycin (mTOR) inhibitors 9 
should be closely monitored when they are administered together with drugs such as 10 
hydroxychloroquine, protease inhibitors or alongside new trial drugs for COVID-19 as they 11 
emerge.  12 
• Early admission should be considered for all LT recipients who develop COVID-19  13 
• Risk factors for a severe course of COVID-19 in LT recipients may include underlying 14 
malignancy, sarcopenia, graft dysfunction and metabolic comorbidities. However, the 15 
individual contributions of these factors require further clarification. 16 
• All patients should receive vaccination for Streptococcus pneumoniae and influenza. 17 
  18 
Hepatocellular carcinoma (HCC)  19 
• The specific risk of COVID-19 in patients with hepatocellular carcinoma remains undefined. 20 
• However, mortality from COVID-19 in cancer patients appears to be determined by age, 21 
gender, and comorbidities as opposed to the use of cytotoxic chemotherapy or other 22 
anticancer treatment [72]. 23 
• Care should be maintained according to guidelines including continuing systemic treatments 24 
and evaluation for liver transplantation.  25 
• Multidisciplinary HCC boards should continue to function remotely and provide treatment 26 
recommendations 27 
• Full HCC surveillance should resume where possible. Where resources remain limited, 28 
patients with increased risk, such as patients with elevated alpha-fetoprotein levels, 29 
advanced cirrhosis, chronic hepatitis B, NASH/diabetes etc should be prioritised in 30 
conjunction with the use of published HCC risk stratification scores.  31 
 32 




Endoscopic procedures are associated with an increased risk of disseminating SARS-CoV-2. 2 
During esophagogastroduodenoscopy (EGD) or endoscopic retrograde cholangiography (ERC), 3 
spreading of virus-containing droplets can occur. In addition, shedding of the virus in the faeces 4 
increases the risk of dissemination during colonoscopy. Thus, depending on the local COVID-19 5 
burden, we recommend SARS-CoV-2 testing prior to endoscopic procedures in all patients. In 6 
patients who test negative and in areas with low COVID-19 burden, EGD - to screen for and 7 
treat varices - and ERC - for duct dilatation or stent replacement in patients after liver 8 
transplantation or patients with primary sclerosing cholangitis - should not be delayed.  9 
In patients with COVID-19, indications for endoscopic procedures should be limited to 10 
emergencies such as gastrointestinal bleeding and bacterial cholangitis.  11 
Ultrasound (HCC surveillance) 12 
HCC surveillance should only be deferred based on available resources (including availability of 13 
therapeutic options in case of HCC diagnosis) at the centre and the individual risk assessment. 14 
Patients with increased risk (e.g. patients with elevated alpha-fetoprotein levels, advanced 15 
cirrhosis, chronic hepatitis B, HCV-related cirrhosis (even after cure), NASH/diabetes) should be 16 
prioritised if resources are limited.  17 
In patients with COVID-19, HCC surveillance can be deferred until after recovery. 18 
Liver biopsy 19 
In areas with low COVID-19 burden, liver biopsies should be performed as indicated, including 20 
grading/staging for MAFLD and chronic viral hepatitis and histological assessment of elevated 21 
transaminases of unknown aetiology. In areas with high COVID-19 burden or limited availability 22 
of resources, biopsy should be prioritised in patients with severely elevated transaminases of 23 
unclear cause (e.g. ALT >5x upper limit of normal), suspected transplant rejection and liver 24 
masses suspicious of malignancy.  25 
In patients with COVID-19, liver biopsy may be performed based on the individual indication for 26 
histological assessment. It has to be considered that treatment/care for COVID-19 may 27 
outweigh the diagnosis of co-existing liver disease and that systemic inflammation associated 28 
15 
 
with COVID-19 is likely to obscure aetiology-specific histologic characteristics. As discussed 1 
above, liver function test abnormalities are common in patients with COVID-19 particularly with 2 
more severe disease and routine liver biopsy in this context is not required.  3 
 4 
6. Liver specific considerations in the pharmacolog ical management of COVID-19  5 
The targeted management of COVID-19 is a rapidly evolving field with a plethora of new or 6 
repurposed medications constantly shifting in and out of favour. In Europe alone there are 7 
currently over 200 registered COVID-19 specific drug trials [73]. This number will no doubt 8 
continue to increase as we learn more about the pathophysiology of the disease. It is beyond 9 
the scope of this updated position paper to comprehensively review the potential therapeutic 10 
options for COVID-19. While some interventions, such as infusion of convalescent plasma or 11 
favipiravir (recently approved in India) show encouraging signals of efficacy, little is known with 12 
regards to liver-specific side effects or contraindications. However, for some therapeutic agents 13 
there are liver-specific considerations which we will discuss. Hepatologists must be mindful of 14 
the secondary effects these drugs may have on the liver and continually evaluate the specific 15 
risks and benefits conferred to their patients with underlying liver disease.  16 
 17 
Remdesivir 18 
Remdesivir is an adenosine-analogue that induces RNA chain termination and was initially 19 
developed as an antiviral agent against Ebola. It has emerged as a promising treatment 20 
candidate against COVID-19 being shown to reduce the duration of symptoms when used early 21 
in the disease course [74, 75]. Despite preclinical investigations demonstrating reversible 22 
aminotransferase elevations [76], use of remdesivir in controlled trials has not demonstrated a 23 
significant impact on liver function tests compared with placebo. In the largest randomised 24 
control trial to date, Beigel et al demonstrated no difference in rates of aminotransferase 25 
elevation between patients taking remdesivir compared with placebo (4% v. 5.9%) [74]. 26 
Similarly, Wang et al also showed comparable rates of elevated transaminases between 27 
remdesivir and placebo groups [77]. Both trials excluded patients with baseline ALT or AST >5x 28 
upper limit of normal and Wang et al. also excluded patients with cirrhosis. Should remdesivir 29 
ultimately move into mainstream use, caution should therefore be exercised in patients with 30 
advanced liver disease or with severe baseline derangements in liver biochemistry, but 31 
otherwise transaminase elevations do not appear to occur over and above what may be 32 
16 
 
expected as part of the typical disease course of COVID-19. Remdesivir is approved for the 1 
treatment of COVID-19 in several European countries. 2 
 3 
Tocilizumab 4 
Interleukin-6 (IL-6) appears to be a key driver of the “cytokine storm” leading to significant lung 5 
and other organ damage in cases of severe COVID-19. Tocilizumab, a humanized monoclonal 6 
antibody targeting IL-6 has therefore been postulated to counter this dysregulated inflammation 7 
and has shown promise in retrospective series of COVID-19 by reducing the need and duration 8 
of organ support [78]. The liver side effect profile of tocilizumab is well established due to its 9 
widespread use in rheumatoid arthritis and other auto-inflammatory conditions. Mild serum 10 
aminotransferase elevations are common and are usually self-limiting and asymptomatic [79], 11 
however, progressive jaundice requiring liver transplantation has been reported [80]. Rarely, 12 
tocilizumab has been associated with Hepatitis B virus reactivation [81] and therefore HBV 13 
serology should form part of routine pre-treatment work-up. 14 
 15 
Corticosteroids 16 
There seems to be a dichotomous relationship between corticosteroids and COVID-19. Whilst 17 
patients already taking corticosteroids may be at increased risk of adverse outcomes from 18 
COVID-19, those with established severe disease seem to paradoxically benefit from 19 
corticosteroid introduction. In patients with inflammatory bowel disease, the use of 20 
corticosteroids has been associated with intensive care unit admission, ventilator requirement 21 
and/or death [19]. Similarly, patients on maintenance glucocorticoids for rheumatological 22 
conditions have an increased rate of hospitalisation following SARS-CoV-2 infection [59]. As 23 
yet, small case series have been unable to draw definitive conclusions regarding the risks 24 
posed by corticosteroid use in patients with autoimmune hepatitis or after liver transplantation 25 
[31, 34]. In these patients, the risks of hepatitis flares or graft rejection must be weighed against 26 
the potential risks of developing severe COVID-19. Currently, we advise against routine 27 
reduction of immunosuppression in AIH or LT recipients, including the use of steroids if 28 
required. Corticosteroids however do appear to be a viable treatment option for patients with 29 
severe COVID-19 requiring respiratory support. In June 2020, the RECOVERY [58] trial 30 
reported that dexamethasone reduced deaths by one-third in ventilated patients and by one fifth 31 
in patients receiving supplemental oxygen. It is likely that this agent will be increasingly used in 32 






Patients with advanced liver disease are at increased risk of venous thromboembolism [82]. 3 
Similarly, coagulopathy is a common abnormality in patients with COVID-19 and has emerged 4 
as a major driver of morbidity and mortality, particularly in patients with severe disease. 5 
Hospitalised patients with COVID-19 have alarmingly high rates of venous thromboembolic 6 
disease with an observed incidence of 20% at day 7, and 42% at day 21 despite 7 
thromboprophylaxis [83]. As well as macro-thrombotic events, COVID-19 is also associated with 8 
widespread micro-thrombosis and endothelial dysfunction contributing to multiorgan failure in 9 
the terminal phase of the disease [84, 85]. The role of anticoagulation in patients with COVID-19 10 
has therefore been extensively investigated and has been shown to improve outcomes in 11 
severe COVID-19 [86], although unified risk stratification models and treatment thresholds have 12 
yet to emerge.  Given that both advanced liver disease and COVID-19 are both associated with 13 
a hypercoagulable state, it reasons that SARS-CoV-2 infection in patients with cirrhosis may 14 
yield a cumulative risk of prothrombotic complications. We therefore suggest that in this 15 
scenario patients should be deemed at particularly high risk of thromboembolic events. Whilst 16 
historically there have been reservations about the use of anticoagulation in patients with 17 
cirrhosis and portal hypertension, systematic review has demonstrated no excess of bleeding 18 
events in anticoagulated patients with cirrhosis and portal vein thrombosis [87]. Furthermore, 19 
anticoagulation may have antifibrotic properties [88] and even confer a survival advantage in 20 
patients with cirrhosis [89]. Further reassurance is provided by a recent multicentre Italian study 21 
in which 80% of patients with cirrhosis and COVID-19 received thromboprophylaxis without any 22 
evidence of major haemorrhagic complications [15]. Whilst thromboprophylaxis, typically with 23 
low molecular weight heparin (LMWH), should form part of standard of care for all patients with 24 
cirrhosis admitted to hospital, it remains to be determined whether patients with COVID-19 and 25 
cirrhosis should receive early treatment with enhanced or therapeutic anticoagulation.   26 
 27 
 28 
Box 1. 29 
Open questions for liver related basic/translationa l research regarding COVID-19 30 
• Risk factors for increased mortality in patients after liver transplantation 31 
• Role of pre-existing immune activation (e.g. in cirrhosis or MAFLD/obesity) in exacerbating 32 
COVID-19 outcomes 33 
18 
 
• Identification of central hubs for SARS-CoV-2 dissemination within the GI-tract and fat 1 
tissues 2 
• Involvement of liver endothelium in promoting SARS-CoV-2 dissemination 3 
• Identification of direct and indirect effects of SARS-CoV-2 on hepatocytes/cholangiocytes 4 
• COVID-19 as a trigger for ACLF and decompensation in cirrhotic patients 5 
• COVID-19 induced thrombophilia as a contributor to progressive liver disease 6 
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Figure legends 16 
Fig. 1 17 
Liver disease progression and poor outcomes from SARS-CoV-2 infection are closely 18 
associated. There must therefore be a concerted effort to resume standard of care and restore 19 
hepatology/transplantation services in order to improve patient outcomes.  20 
 21 
Fig. 2 22 
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Figure 1
All patients with chronic liver disease should adhere to common rules of physical distancing 
Metabolic-dysfunction associated fatty 
liver disease (MAFLD) 
 
• Patients should be made aware of potential 
adverse metabolic and hepatic consequences 
of social isolation including more sedentary 
lifestyles and increased consumption of 
processed foods.  
• Preventing liver disease progression through 
intensive lifestyle intervention, including 
nutritional guidance, weight loss advice, and 
diabetes management may help prevent the 
development of a severe disease course with 
future SARS-CoV-2 infection.  
• Treatment of arterial hypertension should 
continue in accordance with existing 
guidelines. There is currently no evidence 
showing that angiotensin converting enzyme 
inhibitors (ACEIs) or angiotensin receptor 
blockers (ARBs) increase the risk of SARS-
CoV-2 infection or the risk of developing 
severe complications or death from COVID-
19.  
• Early admission should be considered for all 
patients with MAFLD who become infected 
with SARS-CoV-2. 
Autoimmune liver disease 
 
• In patients with autoimmune liver disease, 
we currently advise against reducing 
immunosuppressive therapy. Reductions 
should only be considered under special 
circumstances (e.g. medication-induced 
lymphopenia, or bacterial/ fungal 
superinfection in cases of severe COVID-19) 
after consultation with a specialist. 
• Whilst introducing corticosteroids has shown 
benefit in the treatment of hospitalised 
patients with COVID-19 requiring respiratory 
support, concerns remain that patients who 
are already taking higher doses of 
corticosteroids may be more susceptible to 
SARS-CoV-2 infection and severe COVID-19. 
To minimise systemic glucocorticoid 
exposure we therefore recommend 
considering budesonide as a first-line agent 
to induce remission in patients without 
cirrhosis who have a flare of autoimmune 
hepatitis. 
• In patients treated with corticosteroids who 
develop COVID-19, corticosteroid dosing 
should be sufficient to prevent adrenal 
insufficiency. Addition of, or conversion to 
dexamethasone should only be considered in 
patients with COVID-19 who require 
hospitalisation and respiratory support.   
• There remains a paucity of data to make 
specific recommendations for patients with 
primary biliary cholangitis, primary sclerosing 
cholangitis and IgG4-related disease.  
• All patients should receive vaccination for 
Streptococcus pneumoniae and influenza 
 
Alcohol related liver disease 
 
• Chronic alcohol consumption may increase 
susceptibility of acute respiratory distress 
syndrome (ARDS) secondary to SARS-CoV-2 
infection. 
• Social isolation can lead to new or increased 
alcohol consumption and an increase in 
alcohol related admissions including new 
hepatic decompensation should be 
anticipated during and after periods of 
physical distancing.  
• Clinicians and institutions should therefore 
implement pre-emptive strategies such as 
patient outreach and telephone alcohol 
liaison and cessation services.  
• Whilst introducing corticosteroids has shown 
benefit in the treatment of hospitalised 
patients with COVID-19 requiring respiratory 
support, concerns remain that patients who 
are already taking higher doses of 
corticosteroids may be more susceptible to 
severe COVID-19. These concerns must be 
considered when initiating corticosteroids as 
a treatment for patients with severe 
alcoholic hepatitis.  
• Clinicians should be aware of circulating false 
online misinformation regarding the 
protective effects of alcohol against SARS-
CoV-2 leading to previous instances of 






• Continue treatment of chronic hepatitis C 
virus (HCV) and chronic hepatitis B virus 
(HBV) if already receiving treatment.  
• Use telemedicine/local laboratory testing for 
follow-up visits in patients receiving antiviral 
therapy, send follow-up-prescriptions by mail 
and supply extended prescription supplies 
including full course of direct acting antiviral 
(DAA) medications to complete HCV 
treatment if this has been initiated. However, 
patients with poor compliance with 
medications should be considered for directly 
observed treatment protocols. 
• In patients without COVID-19, treatment for 
HCV and HBV should be initiated according to 
general guidelines  
• Given the unknown impact of interferon 
alpha on systemic inflammation associated 
with COVID-19, alternative agents should be 
considered when initiating treatment for 
patients with HBV during the COVID-19 
pandemic.  
• In patients with COVID-19, initiation of 
treatment for HBV and HCV is usually not 
warranted and should be deferred until 
recovery from COVID-19. 
• In patients with COVID-19 in whom there is 
evidence of high disease activity (flare) or 
clinical suspicion for severe acute HBV 
hepatitis, a decision to initiate antiviral 
therapy should be made on a case-by-case 
basis in consultation with a specialist.  
• In patients with chronic, occult or resolved 
HBV and COVID-19 receiving corticosteroids, 
tocilizumab or other immunosuppressive 
agents, consider the use of antiviral therapy 
to prevent viral flare or reactivation. 
• Continue to work towards the WHO goal of 
eliminating viral hepatitis by 2030 by trying 
to adapt the cascade-of-care to the new 
coronavirus situation and make modifications 





• The specific risk of COVID-19 in patients with 
HCC remains undefined. 
• However, mortality from COVID-19 in cancer 
patients appears to be determined by age, 
gender, and comorbidities as opposed to the 
use of cytotoxic chemotherapy or other 
anticancer treatment. 
• Care should be maintained according to 
guidelines including continuing systemic 
treatments and evaluation for LT 
• Multidisciplinary HCC boards should continue 
to function remotely and provide treatment 
recommendations 
• Full HCC surveillance should resume where 
possible. Where resources remain limited, 
patients with increased risk, such as patients 
with elevated alpha-fetoprotein levels, 
advanced cirrhosis, chronic hepatitis B, 
NASH/diabetes, should be prioritised in 
conjunction with the use of published HCC 
risk stratification scores.  
 
Liver transplant recipients 
 
• LT recipients with underlying malignancy are 
a particular risk of mortality if infected with 
COVID-19 and need to be recognised as a 
group at high risk. 
• We advise against reduction of 
immunosuppressive therapy. Reduction 
should only be considered under special 
circumstances (e.g. medication-induced 
lymphopenia, or bacterial/fungal 
superinfection in case of severe COVID-19) 
after consultation with a specialist. 
• Clinicians must be aware of the high reported 
rates of fear and anxiety regarding COVID-19  
in LT recipients and the barrier this may pose 
to compliance with immunosuppressive 
medication and attendance at scheduled 
medical visits. 
• Drug levels of calcineurin inhibitors and 
mechanistic Target of Rapamycin (mTOR) 
inhibitors should be closely monitored when 
they are administered together with antiviral 
drugs. 
• Early admission should be considered for all 
LT recipients who develop COVID-19   
• All patients should receive vaccination for 
Streptococcus pneumoniae and influenza. 
Cirrhosis 
 
• Patients with cirrhosis are particularly 
vulnerable to both the consequences of 
SARS-CoV-2 infection and to the adverse 
effects of delayed or altered standard of care 
during the COVID-19 pandemic.  
• Every effort should be made to resume the 
best standard of care for patients with 
cirrhosis according to guidelines wherever 
possible. 
• Patients with cirrhosis who are infected with 
SARS-CoV-2 are at high risk of new or 
worsening hepatic decompensation, severe 
COVID-19 and death. 
• All patients with new or worsening hepatic 
decompensation or acute-on-chronic liver 
failure (ACLF) should be prioritised for SARS-
CoV-2 testing even in the absence of 
respiratory symptoms.  
• In those with cirrhosis who are admitted for 
reasons other than COVID-19, particular 
effort should be made to manage these 
patients in a designated non-COVID-19 ward.  
• Guidelines on prophylaxis of spontaneous 
bacterial peritonitis, gastrointestinal 
haemorrhage, and hepatic encephalopathy 
should be closely followed to prevent 
decompensation and avoid admission. 
• Early admission should be considered for all 
patients with cirrhosis who become infected 
with SARS-CoV-2. 
• Because of the potential of circulatory 
dysfunction, the use of vasoconstrictor 
therapy, which is known to increase 
pulmonary pressure and decrease cardiac 
output, should be considered with great 
caution among critically ill patients with 
cirrhosis and COVID-19. 
• Rapid clinical deterioration in patients with 
advanced liver disease and COVID-19 should 
prompt consideration of a symptoms-based 
approach using palliative care guidelines.  
• All patients should receive vaccination for 
Streptococcus pneumoniae and influenza 




• Patients on the LT waiting list with 
decompensated cirrhosis are at high risk of 
severe COVID-19 and death following SARS-
CoV-2 infection. We therefore recommend 
LT centers aim to restore transplantation 
services following the peak of the COVID-19 
epidemic wherever possible.  
• In centers with ongoing resource limitations, 
LT should be prioritized for patients with 
poor short-term prognosis including those 
with acute liver failure, ACLF, high MELD 
score (including exceptional MELDs) and HCC 
at the upper limits of the Milan criteria. 
• The risk of SARS-CoV-2 transmission via liver 
transplantation remains unknown and 
therefore we currently recommend against 
using livers from SARS-CoV-2 infected 
deceased donors.  
• We encourage LT centres to develop and 
improve local and global risk stratification 
pathways for LT donors and recipients 
incorporating a combination of clinical 
history, chest radiology, and SARS-CoV-2 
testing and ethical considerations regarding 
transplantation activities and allocation. 
• Measures should be taken to reduce the risk 
of SARS-CoV-2 infection in the peri-
transplantation period. In areas of high 
disease burden, a COVID-19 free pathway 
through transplantation should be 
implemented including strict social isolation 
for waiting list patients, telephone screening 
before admission, and perioperative 
management in a designated clean ICU 
• Consent for procedures related to 
transplantation should include the potential 
risk of nosocomial COVID-19 and LT 
candidates should be made aware that 
infection with SARS-CoV-2 in patients 
undergoing major surgery is associated with 
an increased risk of severe COVID-19. 
• Living-donor transplantation should be 
considered on a case-by-case basis and 
include careful risk stratification of donor and 
recipient. 
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